(NASDAQ: INO) Inovio Pharmaceuticals's forecast annual revenue growth rate of 522.9% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.57%, and it is also forecast to beat the US market's average forecast revenue growth rate of 10.16%.
Inovio Pharmaceuticals's revenue in 2024 is $832,010.On average, 2 Wall Street analysts forecast INO's revenue for 2024 to be $21,033,329, with the lowest INO revenue forecast at $18,696,292, and the highest INO revenue forecast at $23,370,365. On average, 1 Wall Street analysts forecast INO's revenue for 2025 to be $399,165,834, with the lowest INO revenue forecast at $399,165,834, and the highest INO revenue forecast at $399,165,834.
In 2026, INO is forecast to generate $5,571,027,609 in revenue, with the lowest revenue forecast at $5,571,027,609 and the highest revenue forecast at $5,571,027,609.